557 related articles for article (PubMed ID: 33401585)
1. Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.
Lopez-Beltran A; Cimadamore A; Blanca A; Massari F; Vau N; Scarpelli M; Cheng L; Montironi R
Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33401585
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers for immunotherapy in bladder cancer: a moving target.
Aggen DH; Drake CG
J Immunother Cancer; 2017 Nov; 5(1):94. PubMed ID: 29157296
[TBL] [Abstract][Full Text] [Related]
3. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis.
Rizzo A; Mollica V; Massari F
Eur Urol Focus; 2022 Jan; 8(1):152-159. PubMed ID: 33516645
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors for urothelial carcinoma.
Kim HS; Seo HK
Investig Clin Urol; 2018 Sep; 59(5):285-296. PubMed ID: 30182073
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
[TBL] [Abstract][Full Text] [Related]
7. Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma.
Inokuchi J; Eto M
Cancer Manag Res; 2019; 11():4519-4528. PubMed ID: 31191013
[TBL] [Abstract][Full Text] [Related]
8. Immune check point inhibitors for metastatic urothelial carcinoma: current evidence-based approach for urology daily practice.
Nabar ND; Brandt MP; Thomas C; Tsaur I; Bartsch G; Jaeger W; Haferkamp A; Höfner T
Minerva Urol Nefrol; 2019 Jun; 71(3):205-216. PubMed ID: 30021426
[TBL] [Abstract][Full Text] [Related]
9. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
Koshkin VS; Grivas P
Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
[TBL] [Abstract][Full Text] [Related]
10. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
[TBL] [Abstract][Full Text] [Related]
11. Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day.
Maiorano BA; De Giorgi U; Ciardiello D; Schinzari G; Cisternino A; Tortora G; Maiello E
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203620
[TBL] [Abstract][Full Text] [Related]
12. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
Farina MS; Lundgren KT; Bellmunt J
Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
[TBL] [Abstract][Full Text] [Related]
15. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
[TBL] [Abstract][Full Text] [Related]
16. Treatment Approaches for Cisplatin-Ineligible Patients with Invasive Bladder Cancer.
Einstein DJ; Sonpavde G
Curr Treat Options Oncol; 2019 Feb; 20(2):12. PubMed ID: 30741358
[TBL] [Abstract][Full Text] [Related]
17. Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
Chism DD
J Natl Compr Canc Netw; 2017 Oct; 15(10):1277-1284. PubMed ID: 28982752
[TBL] [Abstract][Full Text] [Related]
18. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibition in upper tract urothelial carcinoma.
Califano G; Ouzaid I; Verze P; Hermieu JF; Mirone V; Xylinas E
World J Urol; 2021 May; 39(5):1357-1367. PubMed ID: 33128595
[TBL] [Abstract][Full Text] [Related]
20. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
